Catalyst Q3 net revenues $102.7M (+79% YoY); non-GAAP EPS $0.49; raises FY revenue guidance to $390-395M

CATALYST PHARMACEUTICALS, INC.

2023-Q3 EPS reported $0.32 revenue$287,636,000

GAAP net loss per diluted share $(0.29) reflects $81.5M one-time IPR&D expense from AGAMREE license acquisition.
Non-GAAP net income $55.9M ($0.49 diluted), up 95% YoY; total net revenues increased 79% to $102.6M.
FDA approved AGAMREE (vamorolone) for Duchenne muscular dystrophy; commercial launch expected Q1 2024.
Raised full-year 2023 total revenue guidance to $390-$395M from prior $370-$380M.
sNDA for FIRDAPSE maximum daily dose increase to 100 mg accepted for filing by FDA; two new FIRDAPSE patents allowed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.